DIOSYNTH ANNOUNCES AGREEMENT WITH IMMUNOGEN, INC.; DIOSYNTH TO MANUFACTURE ANTIBODY FOR IMMUNOGEN

Diosynth Biotechnology, Inc. is pleased to announce the execution of an agreement with ImmunoGen, Inc. (Cambridge, MA) for the production of antibody to be used in the manufacture of ImmunoGen's huN901-DM1 anticancer compound. Under this agreement, Diosynth Biotechnology will undertake technology transfer and conduct process and analytical development work related to production of ImmunoGen's huN901 antibody. Diosynth will then manufacture -- under cGMP -- bulk huN901 antibody for ImmunoGen utilizing the Diosynth cell-culture, fed-batch technology.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1073186XSL_NEWSML_TO_NEWSML_WEB.xml)